Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

Future Oncol. 2015;11(4):557-9. doi: 10.2217/fon.14.268.
No abstract available

Keywords: 53BP1; BRCA1; breast cancer; methylation; ovarian cancer; targeted therapies.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • DNA Damage / drug effects
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Genomic Instability / drug effects
  • Humans
  • Molecular Targeted Therapy*
  • Mutation
  • Neoplasm Grading
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / genetics*
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Poly(ADP-ribose) Polymerase Inhibitors